RAREHealthcare · BiotechnologyThe 20 Wall Street analysts covering Ultragenyx Pharmaceutical, Inc. hold a median 12-month price target of $25 — +67.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 14 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Ultragenyx Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (81): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RARE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +67.8% from it.
Of the 20 most recent actions, 7 moved their price target up and 13 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Sept 2026 | Barclays | Maintains | Overweight | $32 → $35 |
| 21 Sept 2026 | Evercore ISI Group | Maintains | In-Line | $16 → $18 |
| 18 Sept 2026 | Canaccord Genuity | Maintains | Buy | $37 → $39 |
| 18 Sept 2026 | Cantor Fitzgerald | Maintains | Overweight | $33 → $39 |
| 18 Sept 2026 | Citigroup | Maintains | Buy | $31 → $32 |
| 18 Sept 2026 | Morgan Stanley | Maintains | Equal-Weight | $18 → $20 |
| 17 Sept 2026 | Citigroup | Maintains | Buy | $28 → $31 |
| 4 Sept 2026 | Barclays | Maintains | Overweight | $43 → $32 |
| 4 Sept 2026 | Goldman Sachs | Maintains | Neutral | $28 → $19 |
| 3 Sept 2026 | Baird | Downgrade | Neutral | $40 → $16 |
| 3 Sept 2026 | Canaccord Genuity | Maintains | Buy | $83 → $37 |
| 3 Sept 2026 | Cantor Fitzgerald | Maintains | Overweight | $103 → $33 |
| 3 Sept 2026 | Citigroup | Maintains | Buy | $58 → $28 |
| 3 Sept 2026 | Evercore ISI Group | Downgrade | In-Line | $34 → $16 |
| 3 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $50 → $25 |
| 3 Sept 2026 | Jefferies | Maintains | Buy | $77 → $28 |
| 3 Sept 2026 | JP Morgan | Downgrade | Neutral | $80 → $36 |
| 3 Sept 2026 | TD Cowen | Maintains | Buy | $49 → $18 |
| 3 Sept 2026 | Wedbush | Maintains | Neutral | $30 → $23 |
| 3 Sept 2026 | Wells Fargo | Maintains | Overweight | $50 → $18 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RARE appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Ultragenyx Pharmaceutical, Inc. returned −53.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 50% of US stocks
Cheaper than 97% of US stocks
Cheaper than 81% of US stocks
Higher than 77% of US stocks
Higher than 65% of US stocks
Higher than 93% of US stocks
Higher than 19% of US stocks
Higher than 7% of US stocks
Higher than 99% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ultragenyx Pharmaceutical, Inc. has a market value of $1.5B and an enterprise value of $2.4B.
Revenue in the twelve months to 30 June 2026: $717.2M. The latest quarter grew 28.1% year on year.
Net income over the same four quarters: −$586.0M, a −81.7% net margin.
Diluted earnings per share, trailing twelve months: $−5.84.
Free cash flow in the twelve months to 30 June 2026: −$494.0M.
Trailing P/E: −2.6×; forward P/E: 25.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ultragenyx Pharmaceutical, Inc. employs 1,371 people — $523K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ultragenyx Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ultragenyx’s established rare-disease treatments continue to support revenue growth, and two newly approved gene therapies add commercial opportunities.
Why it matters — RARE watchers may view the approved gene therapies alongside existing treatments as part of the company’s growth outlook.
Ultragenyx entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher for $203 million. The company said this was its second PRV sale within one week, after the previously announced GENGLYCOS™ PRV transaction.
Why it matters — The agreement marks another PRV sale by Ultragenyx within a week, a transaction relevant to RARE watchers tracking company developments.
Ultragenyx entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The company says the proceeds will add non-dilutive cash as it advances rare-disease therapies.
Why it matters — The transaction would provide RARE with non-dilutive cash to support its rare-disease therapy programs.
Ultragenyx shares rose more than 3.2% Wednesday morning after the company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The FDA awarded the voucher following approval of GENGLYCOS (DTX401) for glycogen storage disease type Ia.
Why it matters — The agreed voucher sale and its connection to an FDA-approved treatment are developments relevant to RARE shareholders.
Ultragenyx entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The company received the voucher following FDA approval of GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401.
Why it matters — The agreement concerns proceeds from a voucher awarded after FDA approval of Ultragenyx’s treatment for glycogen storage disease type Ia.
The 20 Wall Street analysts covering Ultragenyx Pharmaceutical, Inc. have a median 12-month price target of $25, with estimates ranging from $16 to $39. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 20 analysts covering Ultragenyx Pharmaceutical, Inc., 10 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ultragenyx Pharmaceutical, Inc. 34 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Ultragenyx Pharmaceutical, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (81 of 100).
No one can know that. What the data says: the median 12-month target from 20 analysts implies +67.8% from the last close, and Ticker Nerd's factor model ranks Ultragenyx Pharmaceutical, Inc. 34 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ultragenyx Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RARE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $39 over the next 12 months.
Ultragenyx Pharmaceutical, Inc. returned -53.0% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases.
The most recent item we track (Zacks Investment Research, 14 Oct 2026): "Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?". Ultragenyx’s established rare-disease treatments continue to support revenue growth, and two newly approved gene therapies add commercial opportunities.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Its current portfolio includes approved medicines and other therapies designed to address serious conditions with limited treatment options, spanning metabolic, skeletal, and other inherited disorders. The company works across multiple modalities, including biologics, small molecules, gene therapy, and nucleic acid-based approaches, to target diseases where the underlying biology is well understood and patient need is high. Ultragenyx serves patients through marketed products such as therapies for X-linked hypophosphatemia, long-chain fatty acid oxidation disorders, mucopolysaccharidosis, and homozygous familial hypercholesterolemia. Headquartered in Novato, California, Ultragenyx plays a specialized role in the rare-disease market by combining commercialization capabilities with ongoing research and development in genetic medicine.
CEO Dr. Emil D. Kakkis M.D., Ph.D. · 1,371 employees · United States · https://www.ultragenyx.com
